Wanbond (002082.SZ) subsidiary drug WP107 obtained ethical approval

Zhitong Finance App News, Wanbond (002082.SZ) issued an announcement. The phase I clinical trial of the new drug WP107 to treat myasthenia gravis, a wholly-owned subsidiary of the company, obtained review approval from the Medical Ethics Committee of Yuying Children's Hospital Affiliated to Wenzhou Medical University of the Second Affiliated Hospital of Wenzhou Medical University and approved the launch of the project.

After obtaining the “Drug Clinical Trial Approval Notice” from the State Drug Administration, the company actively promoted pharmacy and clinical work, and has officially launched phase I clinical trials. This time, we received approval from the Medical Ethics Committee of Yuying Children's Hospital Affiliated to Wenzhou Medical University, the Second Affiliated Hospital of Wenzhou Medical University. The aim was to compare the pharmacokinetic characteristics of Huperzine A oral solution and huiferzine A injection in a single dose on an empty stomach in healthy Chinese subjects, and evaluate the relative bioavailability of the oral solution of huxerine A and the safety of the two formulations on an empty stomach.